Related Articles
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement‑positive non‑small cell lung cancer: A case report
ALK inhibitors and advanced non-small cell lung cancer (Review)
Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation (Review)
Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)